TITLE

High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma

AUTHOR(S)
Kraan, W; van Keimpema, M; Horlings, H M; Schilder-Tol, E J M; Oud, M E C M; Noorduyn, L A; Kluin, P M; Kersten, M J; Spaargaren, M; Pals, S T
PUB. DATE
March 2014
SOURCE
Leukemia (08876924);Mar2014, Vol. 28 Issue 3, p719
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents a study which examined the role of deregulated MYD88 signaling in primary testicular lymphomas (PTLs). The study material composed a panel of 37 PTL being diagnosed as diffuse large B-cell lymphoma (DLBCL) according to the classification of the World Health Organization. The study revealed that 25 tumors were discovered to harbor a MYD88 mutation of the studied 37 PTLs.
ACCESSION #
94762958

 

Related Articles

  • The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Chen, Wei-Liang; Tsai, Wen-Chiuan; Chao, Tsu-Yi; Sheu, Lai-Fa; Chou, Jung-Mao; Kao, Woei-Yau; Chen, Yeu-Chin; Ho, Ching-Liang // Annals of Hematology;Jun2010, Vol. 89 Issue 6, p553 

    Several reports have shown a different distribution of malignant lymphoma (ML) in Asian and Western populations. The purpose of our survey was to elucidate whether there are substantial differences in the frequencies of subtypes of ML between different geographical areas. All entities diagnosed...

  • Poster presentations: 2. Cytogenetics.  // Journal of Medical Genetics;Sep2002 Supplement, Vol. 39, pS51 

    Discusses the abstract of the research paper entitled 'A complex case of BCL6 rearrangements in diffuse large cell lymphoma,' by Joan Cunningham, G. Stranks et al and presented during the British Human Genetics Conference at the University of York in England in September 2002.

  • Emerging targets in human lymphoma: targeting the MYD88 mutation. Wang, James Q.; Jeelall, Yogesh S.; Horikawa, Keisuke // Blood & Lymphatic Cancer: Targets & Therapy;2013, Vol. 3, p53 

    B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link between TLR signaling and B cell neoplasm....

  • EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas. Ryan, Russell J. H.; Nitta, Mai; Borger, Darrell; Zukerberg, Lawrence R.; Ferry, Judith A.; Harris, Nancy Lee; Iafrate, A. John; Bernstein, Bradley E.; Sohani, Aliyah R.; Long Phi Le // PLoS ONE;2011, Vol. 6 Issue 12, p1 

    Mutations at codon 641 of EZH2 are recurrent in germinal center B cell lymphomas, and the most common variants lead to altered EZH2 enzymatic activity and enhanced tri-methylation of histone H3 at lysine 27, a repressive chromatin modification. As an initial step toward screening patients for...

  • Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing. Kristensen, Lasse Sommer; Treppendahl, Marianne Bach; Asmar, Fazila; Girkov, Mia Seremet; Nielsen, Helene Myrtue; Kjeldsen, Tina Ellegaard; Ralfkiaer, Elisabeth; Hansen, Lise Lotte; Grønbæk, Kirsten // Scientific Reports;9/27/2013, p1 

    The tumor suppressor genes MGMT and DAPK1 become methylated in several cancers including diffuse large B-cell lymphoma (DLBCL). However, allelic methylation patterns have not been investigated in DLBCL. We developed a fast and cost-efficient method for the analysis of allelic methylation based...

  • MYC Negative Rectal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt's Lymphoma in an Immunocompetent Patient. Parikh, Jignesh G.; Strom, Ted; Stone, Ilya // Case Reports in Pathology;2013, p1 

    B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma (BLUI) is a recently added entity to the World Health Organization (WHO) classification to address a grey zone between large B-cell lymphoma (DLBCL) and Burkitt's lymphoma...

  • A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. Sanders, Lucinda; Jayne, Sandrine; Kennedy, Ben; Miall, Fiona; Aukema, Sietse M.; Siebert, Reiner; Wagner, Simon D.; Dyer, Martin J. S. // Case Reports in Hematology;2014, p1 

    The WHO classification of lymphomas allows for a group of diseases that have features intermediate between those of Burkitt lymphoma and diffuse large B-cell lymphoma. These are a diverse group of diseases whose genetics and clinical course are yet to be fully described. We report an unusual...

  • ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Beltran, Brady; Castillo, Jorge; Salas, Renzo; Quiñones, Pilar; Morales, Domingo; Hurtado, Fernando; Riva, Luis; Winer, Eric // Journal of Hematology & Oncology;2009, Vol. 2, p1 

    Background: Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma (ALK-DLBCL) is a rare lymphoma with several clinicopathological differences from ALK-positive anaplastic large cell lymphoma (ALCL). The latest WHO classification of lymphomas recognizes ALK-DLBCL as a separate entity....

  • Burkitt Lymphoma and Diffuse Aggressive B-Cell Lymphoma. Forteza-Vila, Jerónimo; Fraga, Máximo // International Journal of Surgical Pathology;Jun2010 Supplement 3, Vol. 18 Issue S2, p133S 

    The article presents a comparison between the pathological aspects of Burkitt lymphoma (BL) and diffuse aggressive B-cell lymphoma (DLBCL). It notes that the World Health Organization (WHO) has classified lymphomas through differentiating between the lineage of T-cell and B-cell among...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics